|
|
|
 |
|
|
 |
|
|
| |
 |
| |
 |
| |
| |
 |
| Sirna Therapeutics, Inc. (RNAI) |
OBP IV |
(Acquired by Merck & Co. Inc.)
(Formerly Ribozyme Pharmaceuticals)
San Francisco, CA
www.sirna.com
Sirna develops therapeutics based on RNA interference (RNAi) technology, a new and extremely potent method of using nucleic acids as drugs. Sirna’s technology allows the rapid development of drugs against otherwise challenging drug targets. Currently Sirna has drug development programs in macular degeneration, oncology, diabetes, asthma, dermatology, and other areas.
|
|
| |
|
|
|
|
|
